The United States questions the efficacy of the AstraZeneca Covid vaccine: The US National Institute of Allergy and Infectious Diseases (NIAID) has shown “concern” because it believes AstraZeneca may have included “outdated information” in the trials of its Covid-19 coronavirus vaccine, thus that your efficacy data would be incomplete and you have requested more data.
“We urge the company to work with the Data and Security Monitoring Board (DSMB) to review the efficacy data and ensure that the figures are more accurate and up-to-date made public as soon as possible,” says the NIAID statement.
Authorization and guidelines for the vaccine’s use in the United States will be determined after a thorough review of the data by independent advisory committees, the text adds.
See This: www.peryourhealth.com login
This questioning occurs shortly after Spain has decided to extend vaccination with AstraZeneca until age 65 and five days after the European Medicines Agency (EMA) defended the safety and efficacy of the pharmaceutical product against the Covid coronavirus. 19.
According to the latest data provided by the Ministry led by Carolina Darias, 1,927,400 doses of the drug have already been distributed among the autonomous communities and a total of 981,123 have been administered. Some, such as Madrid, had already asked the Ministry of Health to apply the Astrazeneca drug also to those over 65.
Although, so far, the phase III trial that the company has carried out in the United States shows that the Astrazeneca vaccine is 80 percent effective in people over 65 years of age. According to this work, the vaccine demonstrated a statistically significant 79 percent efficacy in preventing symptomatic Covid-19 and 100 percent efficacy in preventing severe disease and hospitalization. However, the United States needs more up-to-date information.
Stay in touch at peryourhealth site for getting more updates.